OTC Markets OTCQB - Delayed Quote USD

Vycor Medical, Inc. (VYCO)

Compare
0.0511 -0.0089 (-14.83%)
At close: November 21 at 3:25 PM EST
Loading Chart for VYCO
DELL
  • Previous Close 0.0600
  • Open 0.0511
  • Bid 0.0510 x --
  • Ask 0.0980 x --
  • Day's Range 0.0511 - 0.0511
  • 52 Week Range 0.0330 - 0.1280
  • Volume 1,000
  • Avg. Volume 6,796
  • Market Cap (intraday) 1.705M
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) --
  • EPS (TTM) -0.0100
  • Earnings Date Nov 13, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Vycor Medical, Inc. designs, develops, and markets neurological medical devices and therapies in the United States and Europe. It operates through two segments: Vycor Medical and NovaVision. The Vycor Medical segment provides devices for neurosurgery comprising ViewSite Brain Access System, a retraction and access system for brain and spine surgeries. The NovaVision segment offers non-invasive computer-based rehabilitation targeted at people who have impaired vision as a result of stroke or other brain injury. It has a license agreement which grants for the license to provide NovaVision's products and therapies to patients and professionals in Germany, Austria and Switzerland. It primarily serves hospitals and medical professionals. Vycor Medical, Inc. was founded in 2005 and is headquartered in Boca Raton, Florida. Vycor Medical, Inc. is a subsidiary of Fountainhead Capital Management Limited.

www.vycormedical.com

8

Full Time Employees

December 31

Fiscal Year Ends

Recent News: VYCO

View More

Performance Overview: VYCO

Trailing total returns as of 11/21/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

VYCO
33.64%
S&P 500
24.72%

1-Year Return

VYCO
36.12%
S&P 500
30.82%

3-Year Return

VYCO
45.64%
S&P 500
26.62%

5-Year Return

VYCO
65.93%
S&P 500
91.37%

Compare To: VYCO

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: VYCO

View More

Valuation Measures

Annual
As of 11/20/2024
  • Market Cap

    3.27M

  • Enterprise Value

    4.20M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    2.22

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    2.91

  • Enterprise Value/EBITDA

    63.34

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    --

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    --

  • Diluted EPS (ttm)

    -0.0100

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    --

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    --

Research Analysis: VYCO

View More

Company Insights: VYCO

Research Reports: VYCO

View More

People Also Watch